肾动脉支架置入术后肾功能恢复改善无事件生存:肾动脉粥样硬化病变心血管结局试验亚组分析
该研究为CORAL试验的事后分析,纳入842例基线慢性肾脏病2至4期患者,随机分为单纯最佳药物治疗组(432例)或肾动脉支架置入联合最佳药物治疗组(410例)。支架联合药物组肾功能改善(eGFR较基线增加≥20%)比例高于单纯药物组(25.6% vs 17.1%,P=0.003),但两组无事件生存无差异(P=0.18)。在支架组中,肾功能应答者无事件生存优于无应答者(P=0.009)。
要点
- 支架联合药物组肾功能改善比例高于单纯药物组(25.6% vs 17.1%,P=0.003)。
- 两组无事件生存无显著差异(P=0.18)。
- 支架组中应答者无事件生存优于无应答者(P=0.009)。
核心结论
- CORAL试验中接受肾动脉支架置入联合最佳药物治疗后肾功能改善的患者无事件生存得到改善。
- 该发现强化了需要结局预测因素来指导肾动脉支架置入患者选择的必要性。
研究设计与样本
- CORAL试验的事后分析,该试验为多中心随机对照试验,共纳入947例患者。
- 本分析纳入842例基线慢性肾脏病2至4期患者,随机分为单纯最佳药物治疗组(n=432)或肾动脉支架置入联合最佳药物治疗组(n=410)。
- 根据基线至末次随访(中位3.6年,四分位距2.6-4.6年)的eGFR变化将患者分为应答者(eGFR较基线增加≥20%)和无应答者。
- 无事件生存定义为无死亡及多种心血管和肾脏并发症。
主要发现
- 肾动脉支架置入联合最佳药物治疗组肾功能改善(eGFR较基线增加≥20%)的患者比例高于单纯最佳药物治疗组(25.6% vs 17.1%;P=0.003)。
- 两组无事件生存无差异(log-rank检验P=0.18)。
- 在支架置入队列中,多变量Cox回归识别出四个与无事件生存独立相关的变量:较高的术前eGFR(风险比0.98;95%CI 0.96-0.99;P=0.002)和支架置入应答者(风险比0.49;95%CI 0.26-0.95;P=0.033)增加无事件生存;而充血性心力衰竭病史(风险比2.52;95%CI 1.46-4.35;P<0.001)和较高的术前收缩压(风险比1.02;95%CI 1.01-1.03;P=0.002)降低无事件生存。
- 在支架置入组中,410例患者中有105例(25.6%)为应答者,应答者的无事件生存优于无应答者(log-rank检验P=0.009)。
- 支架置入后肾功能改善的唯一独立术前负面预测因素是糖尿病(比值比0.37;95%CI 0.16-0.84;P=0.017),其降低肾动脉支架置入联合最佳药物治疗后肾功能改善的概率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial, a multicenter randomized controlled trial with 947 patients, concluded that there was no benefit of renal artery stenting (RAS) over medical therapy. However, patients with chronic kidney disease (CKD) were not analyzed separately in the CORAL trial. CKD is a risk factor for cardiovascular and renal morbidity. We hypothesized that improved renal function after RAS would be associated with increased long-term survival and a lower risk of cardiovascular and renal events in patients with CKD. METHODS: This post hoc analysis of the CORAL trial included 842 patients with CKD stages 2 to 4 at baseline who were randomized to optimal medical therapy alone (OMT; n = 432) or RAS plus OMT (RAS + OMT; n = 410). Patients were categorized as responders or nonresponders based on the change in the estimated glomerular filtration rate (eGFR) from baseline to last follow-up (median, 3.6 years; interquartile range, 2.6-4.6 years). Responders were defined by a 20% or greater increase in eGFR from baseline; all others were designated as nonresponders. Event-free survival was defined as freedom from death and multiple cardiovascular and renal complications. Event-free survival was analyzed using the Kaplan-Meier method and log-rank test. Multivariable Cox proportional hazards regression analysis was used to identify independent predictors of event-free survival. RESULTS: The RAS + OMT group had a higher proportion of patients with improved renal function (≥20% increase in eGFR over baseline), compared with the OMT group (25.6% vs 17.1%; P = .003). However, event-free survival was no different for the two cohorts (P = .18 by the log-rank test). Multivariable Cox proportional hazards regression analysis identified four variables that independently correlated with event-free survival for the stented cohort. Higher preoperative eGFR (hazard ratio, 0.98; 95% confidence interval [CI], 0.96-0.99; P = .002) and being a responder to stenting (hazard ratio, 0.49; 95% CI, 0.26-0.95; P = .033) increased event-free survival, whereas a history of congestive heart failure (hazard ratio, 2.52; 95% CI, 1.46-4.35; P < .001) and a higher preoperative systolic BP (hazard ratio, 1.02; 95% CI, 1.01-1.03; P = .002) decreased event-free survival. Within the stented group, 105 of 410 patients (25.6%) were responders. Event-free survival was superior for responders, compared with nonresponders (P = .009 by log-rank test). The only independent preoperative negative predictor of improved renal function after stenting was diabetes (odds ratio, 0.37; 95% CI, 0.16-0.84; P = .017), which decreased the probability of improved renal function after RAS + OMT. A subset of patients (23.4%) after RAS had worsened renal function, but OMT alone produced an equivalent incidence of worsened renal function. An increased urine albumin/creatinine ratio was an independent predictor of worsened renal function after RAS. CONCLUSIONS: CORAL participants who demonstrated improved kidney function after RAS + OMT demonstrated improved event-free survival. This finding reinforces the need for predictors of outcome to guide patient selection for RAS.
引用
- Modrall JG, Zhu H, Prasad T, et al. Retrieval of renal function after renal artery stenting improves event-free survival in a subgroup analysis of the Cardiovascular Outcomes in Renal Atherosclerotic Lesions trial. J Vasc Surg. 2023. PMID: 36736864. doi:10.1016/j.jvs.2022.12.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。